XPNPEP2

Across TCGA pan-cancer cohorts, XPNPEP2 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated XPNPEP2 data layer compared with 29 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher XPNPEP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated XPNPEP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

BLCA, COAD, and UCEC are the cancer types where XPNPEP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.149	0.710	.003	36	view →
COAD	OS	Median	All	0.111	0.871	<.001	20	view →
UCEC	DFS	Median	All	0.975	0.600	.001	16	view →
PRAD	DFS	Median	All	0.508	0.936	<.001	12	view →
LUSC	DFS	Median	II,III,IV	1.000	0.370	.008	7	view →
CESC	OS	Median	II,III,IV	0.203	0.759	.021	6	view →
LIHC	OS	Median	All	0.164	0.704	.025	6	view →
LUAD	OS	Median	III,IV	0.158	0.660	.019	6	view →
SKCM	OS	Median	All	0.576	0.793	.011	4	view →
SCLC	OS	Median	All	1.000	0.330	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

XPNPEP2–BLCA (OS)

Open the BLCA breakdown →